Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Jing Zhang, Yan Gu, Baoan Chen Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People’s Republic of ChinaCorrespondence: Baoan Chen, Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People’s...
Main Authors: | Zhang J, Gu Y, Chen B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-02-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/drug-resistance-mechanism-and-new-targeted-drugs-and-treatments-of-rel-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018-05-01) -
Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01) -
Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
by: Yingnan Si, et al.
Published: (2021-08-01) -
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
by: Upasana Ray, et al.
Published: (2023-04-01) -
Targeted drug conjugates in cancer therapy: Challenges and opportunities
by: Geng Jia, et al.
Published: (2024-12-01)